Total Reports
24
Below-median volume
Dog /
Breed profile · FDA CVM July 2026 extract
Kuvasz adverse-event record
Adverse-event filings for Kuvasz (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.
- #347 of 510
- by report volume (all breeds)
- 24
- FDA CVM reports on file
- 8.3%
- death-coded share of reports
- 5
- Vomiting - top reaction
How the 24 reports break down
By recorded gender -- every report on file for Kuvasz, no filtering.
Annual report volume
Data updated September 2026
The verdict
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Kuvasz ranks #344 of 510 by total reports (24). Death-coded-share rank requires at least 50 reports. National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).
- 93,675
- Retriever - Labrador reports (#1)
- 99.0%
- Atlantic Salmon (Salmo salar) death share (#1)
- #344
- This breed, reports of 510
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Kuvasz has 24 reports now versus 24 in that prior snapshot: 0 the same number of (0.0%).
- Report change
- +0
- Death-coded reports
- +0
- Death-coded share
- +0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Kuvasz changesDeaths Reported
2
of 24 reports
Death-coded share of reports
8.3%
8.3% death-coded
Avg Age at Report
6.4 yr
41.1 kg avg weight
Death-Coded Outcome Share
Kuvasz death-coded reports 8.3%
Cross-breed median
8.3% of 24 kuvasz reports involved a death outcome.
How to read this number
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
Average weight at time of report: 41.1 kg (90.6 lbs)
Top Reported Reactions
Vomiting 5
Other abnormal test result NOS 5
Anorexia 4
Lack of efficacy (endoparasite) - heartworm 4
Lethargy (see also Central nervous system depression in 'Neurological') 3
Most Referenced Drugs
Fluralaner Chew Tablets 4
Milbemycin Oxime + Spinosad 3
Trilostane 2
Moxidectin 2
Carprofen 2
Outcome Breakdown
Ongoing
9 (42.9%)
Outcome Unknown
5 (23.8%)
Recovered/Normal
3 (14.3%)
Euthanized
2 (9.5%)
Recovered with Sequela
2 (9.5%)
Gender Distribution
Female 12 (50.0%)
Male 12 (50.0%)
Reports by Year
| Year | Reports | Trend |
|---|---|---|
| 2010 | 3 | |
| 2012 | 1 | |
| 2013 | 3 | |
| 2014 | 3 | |
| 2015 | 2 | |
| 2016 | 3 | |
| 2017 | 2 | |
| 2019 | 1 | |
| 2020 | 4 | |
| 2023 | 1 | |
| 2024 | 1 | |
Kuvasz: high death-coded share in the FDA CVM extract
Signature read: Kuvasz's 8.3% death-coded share is in the upper third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Kuvasz sits at #347 of 510 by report volume among all breeds and #226 of 298 among dog breeds, with 24 reports and 2 (8.3%) death-coded. Mean age at report: 6.4 years, average weight 41.1 kg (90.6 lbs).
Top reported signs: Vomiting (5), Other abnormal test result NOS (5), Anorexia (4). Most-referenced drug: Fluralaner Chew Tablets (4 reports), followed by Milbemycin Oxime + Spinosad (3) and Trilostane (2).
Outcome coding on 21 status-recorded reports is dominated by Ongoing (42.9%). Annual submissions ranged 1-2,024 across 11 years on file.
Dog Breeds With a Similar Report Volume
Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.
Nationwide breeds with similar profiles
Sparse-volume peer sets for Kuvasz drawn from openFDA outside the Dog family so the neighborhoods are not species containment (the similar-volume list above stays within species).
Similar average weight
Nearest other-species breeds by reported average weight (41.1 kg here).
What to do with this dog
- Compare Kuvasz's report volume and death-coded share against similar-volume breeds nationwide. See similar breeds
- Read how death-coded share differs from a mortality rate before drawing conclusions. Breed-specific risks guide
- Browse every dog breed we track for comparison. All dog breeds
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Frequently Asked Questions
How many FDA adverse event reports involve Kuvasz? ▼
There are 24 adverse event reports involving Kuvasz in the FDA database, of which 2 were death-coded (8.3% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Kuvasz ranks #347 of 510 by report volume among all breeds PlainBreed indexes (#226 of 298 among dog breeds).
Where does Kuvasz sit among other breeds in PlainBreed's corpus? ▼
According to FDA CVM report volume, Kuvasz is #347 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Dog, it is #226 of 298. It has fewer than 50 reports, so it is outside the death-rate ranking cohort (≥50 reports). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Kuvasz? ▼
The most commonly reported adverse reactions for Kuvasz are Vomiting (5 reports), Other abnormal test result NOS (5 reports), Anorexia (4 reports), Lack of efficacy (endoparasite) - heartworm (4 reports), Lethargy (see also Central nervous system depression in 'Neurological') (3 reports).
What drugs are most frequently associated with Kuvasz adverse events? ▼
The drugs most frequently referenced in Kuvasz adverse event reports are Fluralaner Chew Tablets (4 reports), Milbemycin Oxime + Spinosad (3 reports), Trilostane (2 reports), Moxidectin (2 reports), Carprofen (2 reports).
What is the average age of Kuvasz in adverse event reports? ▼
The average age of Kuvasz at the time of adverse event reports is 6.4 years, with an average weight of 41.1 kg (90.6 lbs).
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
openFDA Animal & Veterinary Adverse Events (FDA CVM) for Kuvasz (Dog), extract as of July 2026 extract. 24 reports · 2 death-coded (8.3% of reports, not a mortality rate) · #347 of 510 by volume.
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →